PT-141
Bremelanotide
PT-141 (bremelanotide) is a first-of-its-kind sexual-health peptide — it works on <b>desire in the brain</b>, not blood flow, which makes it fundamentally different from Viagra-style drugs. It's even FDA-approved (as Vyleesi) for a specific indication. This guide covers how PT-141 works, what the research shows, dosing references, safety and status.
PT-141 quick facts
| Reported research dosing | 0.5mg-2mg |
| Route | Subq |
| Cycle length | - |
| Frequency | As Needed · As Needed |
| Half-life | ~2–3 hrs |
| Forms | Injectable, Nasal |
| Evidence level | FDA-approved (Vyleesi); human |
Central libido lever for men and women. Flushing/nausea track with dose — start low.
How PT-141 works
PT-141 is derived from alpha-melanocyte-stimulating hormone (α-MSH) and acts as a melanocortin-receptor agonist, primarily at MC4R in the hypothalamus and limbic system — the brain circuitry behind sexual desire and arousal. The crucial distinction: it works centrally on desire, not on vascular smooth muscle. That's what separates it mechanistically from PDE5 inhibitors like sildenafil (Viagra) and tadalafil, which act on blood flow. PT-141 targets the 'wanting,' not just the 'plumbing.'
What the research & approval show
PT-141 has real clinical validation: as Vyleesi, bremelanotide was FDA-approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first approved on-demand treatment for HSDD. Because its mechanism is desire-based and central, off-label interest has expanded to men with low libido or erectile dysfunction that doesn't fully respond to PDE5 inhibitors, and it's sometimes combined with them since the mechanisms are complementary.
PT-141 dosing (research reference)
As the approved Vyleesi, bremelanotide is given by subcutaneous auto-injector on demand, at least 45 minutes before anticipated activity, with a defined maximum frequency (not daily). Research-market PT-141 is also seen in nasal-spray form. It's reconstituted with bacteriostatic water where injectable; the calculator above converts a research amount into syringe units. This summarizes existing references for education only, not dosing advice.
Safety & side effects
The most common effects are nausea (fairly frequent, especially early), flushing and headache. Because it acts on melanocortin receptors, it can cause a transient rise in blood pressure (so it's cautioned in uncontrolled hypertension or cardiovascular disease) and, via MC1R, temporary skin/gum darkening with repeated use. These are worth understanding before use, and it's a prescription product for a reason.
Related compounds
PT-141 shares the melanocortin family with the tanning peptides Melanotan I/II (which hit MC1R for pigmentation). For sexual health specifically, PT-141 is unique in acting on desire centrally rather than on blood flow like the PDE5-inhibitor drugs.
Legal & regulatory status
Bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women — a prescription medication. Use outside that indication (e.g., in men) is off-label, and PT-141 sold on the research-chemical market is unapproved research material. Follow the laws and medical guidance that apply to you.
Where to get PT-141
PT-141 is sold in 3 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
PT-141 reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for PT-141
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women, on the RECONNECT phase-3 program. The effect size was statistically significant and modest — a meaningful improvement for a minority rather than a transformation for most.
- Nausea was the dominant adverse event, affecting roughly 40% of participants and causing a substantial share of the discontinuations.
📊 Correlative data
- Used far beyond the licensed population — men, and women outside the approved indication — where there are no trials. Reported experience is consistent about two things: it works on desire rather than on mechanics, and the nausea is dose-related and real.
- Flushing and transient blood-pressure rise are frequently reported, matching the trial data.
🧪 Theoretical / extrapolated
- A melanocortin receptor agonist acting centrally — on MC3R and MC4R in the hypothalamus — not on vascular smooth muscle. That is the key mechanistic distinction from the PDE5 inhibitors: it addresses desire, they address blood flow, and they are not substitutes for each other.
- MC1R activity is why some users report darkening of moles and freckles, and the shared melanocortin mechanism is why stacking it with Melanotan is predicted to compound that.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What PT-141 actually does
Bremelanotide is the only melanocortin agonist that has been through two phase 3 trials for a behavioral endpoint, and the receptor it works through is the body's satiety receptor. That sentence explains the drug and every complaint about it.
Where it acts. Not on vascular smooth muscle, which is what makes it categorically different from a PDE5 inhibitor. It is a melanocortin receptor agonist acting on hypothalamic neurons, and the circuit has been dissected in mice with unusual precision. Female mice lacking MC4R approached males less and had reduced receptivity, and the deficit was independent of body weight. Re-expressing MC4R only on Sim1 neurons normalized receptivity but left approach behavior unchanged; re-expressing it only on oxytocin neurons greatly increased approach behavior and improved receptivity Semple 2023.
Read that dissociation slowly, because it is the mechanism. Two anatomically separate MC4R populations carry two separable halves of the behavior, and neither of them runs through the metabolic circuitry — the authors state explicitly that the effects were independent of melanocortin-driven metabolic effects. A drug hitting MC4R everywhere at once is therefore hitting at least three distinct neuronal populations with three different outputs, which is why the clinical picture is a modest desire effect arriving alongside nausea in a large fraction of people.
The oxytocin-neuron finding is the most interesting line in the melanocortin literature and almost nobody in this market has read it. It says melanocortin signaling reaches its behavioral output partly through oxytocin neurons Semple 2023 — which makes the common stack of this compound with intranasal oxytocin a mechanistic question rather than an additive one. Two agents aimed at one node are not two mechanisms.
What the molecule is. A cyclic melanocortin agonist whose primary metabolic route is repeated hydrolysis of the amide bond of the cyclic peptide Vyleesi label. It is only 21% bound to human serum protein, which means most of what is in plasma is free drug — unusual, and it is why the exposure curve is as steep as it is.
Cell, rodent, human — and where it stops
Step one, receptor. MC4R is a Gs-coupled melanocortin receptor; the family's pharmacology and the consequences of activating it are settled well enough that approved agonists now exist for four separate indications Böhm 2024.
Step two, mice, with the circuit taken apart. MC4R knockout, then targeted re-expression on Sim1 neurons and on oxytocin neurons Semple 2023. Species: mouse. Manipulation: genetic, not pharmacological. Readout: lordosis quotient and approach behavior. That is a clean mechanism experiment and it is not a drug study.
Step three, phase 3 — and the numbers are the reason this page exists. RECONNECT was two identical randomized, double-blind, placebo-controlled trials of 1.75 mg subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder, randomized 1:1 to 24 weeks. 1,267 women randomized; 1,247 in the safety population and 1,202 in the modified intent-to-treat efficacy population; mean age 39; 85.6% white; 96.6% from US sites Kingsberg 2019.
The effect sizes, printed rather than described. Coprimary endpoints were change from baseline in the Female Sexual Function Index desire domain and in item 13 of the Female Sexual Distress Scale. Desire: +0.30 (study 301, P<.001) and +0.42 (study 302, P<.001), integrated +0.35. Distress: −0.37 and −0.29, integrated −0.33 Kingsberg 2019. Those are placebo-adjusted changes on scales whose desire domain runs from 1.2 to 6.0. Statistically unambiguous across 1,202 people, and small. The trials were funded by the sponsor and its commercial partner, which is stated in the paper and is normal, and is also the reason to read the numbers rather than the conclusion sentence.
Step four, the same receptor measured for a different outcome. Two phase 1 randomized controlled trials in premenopausal women with a BMI over 30 found total caloric intake down 398 to 469 kcal/day against placebo and weight down 1.3 kg at 16 days in one study and 1.7 kg versus 0.9 kg in the other Spana 2022. This is the same drug, the same receptor, a different endpoint — and it is the cleanest available evidence that the nausea and the desire effect cannot be separated by dose selection.
The obstacles. (1) The approved population is premenopausal women. There is no phase 3 in men and none in postmenopausal women, and that is where most non-prescription use sits. (2) The comparator with the larger evidence base in women is systemic testosterone, which a society guideline supports with the caveat that a total testosterone level should not be used to diagnose the condition and that current research supports a moderate therapeutic benefit Parish 2021. (3) The trials ran 24 weeks; there is no controlled multi-year data. (4) Everything above is subcutaneous injection; nothing here supports any other route.
PT-141 pharmacokinetics — how much of it actually gets in
This is one of the few compounds in the Vault whose pharmacokinetics are fully published, because it is an approved drug. Here is the whole curve.
The numbers. After a single 1.75 mg subcutaneous dose, mean Cmax 72.8 ng/mL, AUC 276 hr·ng/mL, median Tmax approximately 1.0 hour, mean terminal half-life approximately 2.7 hours, mean volume of distribution 25.0 ± 5.8 L, and only 21% bound to human serum protein Vyleesi label. Elimination after a radiolabeled dose: 64.8% in urine, 22.8% in feces. The metabolic route is not a cytochrome — it is repeated hydrolysis of the amide bond of the cyclic peptide, which is peptidase chemistry, not liver oxidation.
What a 25 L volume of distribution tells you. Total body water in a 70 kg adult is roughly 42 L and plasma volume is about 3 L. A Vd of 25 L means the drug leaves the circulation and distributes into tissue rather than sitting in plasma, but it is nowhere near the hundreds of liters that indicate deep tissue sequestration. Combined with 21% protein binding and a 2.7-hour half-life, this is a compound that arrives fast, spreads into extracellular space, and is gone: five half-lives is under 14 hours, which is why the label's dosing instruction is at least 45 minutes before, and no more than one dose per 24 hours.
The oral question, answered by structure. There is no oral form and there cannot easily be one. A cyclic peptide cleared by amide hydrolysis meets gastric pepsin, pancreatic proteases and brush-border peptidases before absorption, and whatever survives faces first-pass hepatic extraction. The injectable route is not a preference; it is the only route with measured bioavailability.
And the hemodynamic curve, which is separate from the drug curve. The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours post dose, and a reduction in heart rate of up to 5 beats per minute, with both back to baseline usually within 12 hours Vyleesi label. Note the mismatch: plasma peaks at 1 hour and blood pressure peaks at 2 to 4 hours. The cardiovascular effect trails the exposure, so it is downstream signaling rather than a direct concentration effect — and a person who measures blood pressure at the one-hour mark and finds it normal has measured the wrong time point.
What would have to be true, and how you would know it was not
Three predictions with a marker, a direction and a window. The third is the one that argues against off-label use.
1. Total testosterone should not change, and if that holds it settles an argument. The commonest lay explanation for this compound is that it ‘raises hormones’. The mechanism says otherwise: the target is a hypothalamic receptor whose behavioral output was shown in mice to be independent of the metabolic circuitry Semple 2023, and the guideline literature is explicit that a total testosterone level does not diagnose the condition this drug treats Parish 2021. Prediction: total testosterone and SHBG drawn at baseline and at 8 weeks, at the same time of morning, are unchanged. If they move, something other than melanocortin agonism is in the vial.
2. Prolactin is the marker that could explain a non-response, and nobody checks it first. Hyperprolactinemia is one of the few genuinely correctable endocrine causes of low desire, and it is a single morning draw. Prediction: in a person with an elevated prolactin, a melanocortin agonist will underperform, because it is acting downstream of a signal that is being actively suppressed upstream. That is falsifiable in either direction and it costs one tube of blood before spending anything on the drug.
3. Against the product: appetite and weight should fall, and the pigmentation figure everybody quotes is conditioned on a dosing ceiling that off-label use ignores. On the appetite half, the same molecule cut intake by roughly 400 kcal/day in controlled trials Spana 2022 — so predict a measurable fall in fasting insulin and body weight in a frequent user, and treat that as evidence the systemic arm is engaged rather than as a bonus. On the pigmentation half, the label reports focal hyperpigmentation of the face, gingiva and breasts in 1% of patients who received up to 8 doses per month, with higher risk on daily dosing and in people with darker skin, and resolution not confirmed in all patients after discontinuation Vyleesi label. The 1% is a number attached to eight doses a month. Prediction: at daily or near-daily frequency the incidence is materially higher, and the way to find out is a photographed baseline of face and gums, not a memory.
What nobody has tested yet
Four things that could be measured and have not been.
What the dose-response looks like above and below 1.75 mg. One dose went through phase 3 and one dose is on the label Vyleesi label. The Vault card's 0.5–2 mg range is community practice, and there is no published curve relating dose to the desire endpoint or to the nausea rate. Whether a 0.5 mg dose retains any of the 0.35-point effect while dropping the 40% nausea is the single most useful unanswered question about this drug, and it is answerable with an ordinary dose-ranging design.
Whether it does anything in men, measured properly. There is no phase 3 in men. The mouse circuit work was done in females Semple 2023, and the two MC4R populations that carry receptivity and approach behavior have not been mapped the same way in males of any species. ‘It works in men too’ is an inference from a receptor being present, which is the weakest kind of inference there is.
Whether the oxytocin-neuron route means the common stack is redundant. If melanocortin signaling reaches approach behavior through oxytocin neurons Semple 2023, then adding exogenous oxytocin is either additive, redundant or competitive, and there is no experiment in any species that distinguishes those three. It would take one crossover study with a behavioral endpoint.
Whether repeat dosing shifts the blood-pressure curve. The label's hemodynamic data describes what happens after a dose Vyleesi label. What happens to 24-hour ambulatory blood pressure in someone dosing several times a week for a year has not been published, and it is the measurement that would matter most for the population using this outside its indication.
PT-141 — its own safety story, not its class's
Two of this drug's three real risks are printed on its own label, and the third is created by using it outside the population the label describes.
Nausea is not a minor tolerability note. In the trials it was reported by 40% of treated patients, required anti-emetic therapy in 13%, and led to premature discontinuation in 8% Vyleesi label. One in twelve people who started stopped because of it. That is the same MC4R signaling that produces the appetite effect Spana 2022, so it is not separable by choosing a cleaner batch.
The cardiovascular contraindication is absolute on the label and is the one that off-label supply removes. The drug is contraindicated in uncontrolled hypertension or known cardiovascular disease Vyleesi label. A prescriber applies that contraindication; a website does not. The effect it protects against is modest in a healthy person — 6 mmHg systolic, peaking at 2 to 4 hours — and modest is a statement about the population studied, which excluded the people the contraindication names.
Pigmentation, and why the number in circulation is optimistic. Focal hyperpigmentation of the face, gingiva and breasts was reported in 1% at up to eight doses per month, with explicitly higher risk on daily dosing and in darker skin, and resolution after stopping not confirmed in all patients Vyleesi label. This is MC1R cross-activation, the same receptor that drives the tan on the melanotan page, and it is the mechanism telling you that the two compounds are not as different as their marketing.
Dosing frequency is where the label and the market diverge most. The label caps use at one dose per 24 hours and recommends no more than eight doses per month Vyleesi label. Every safety percentage quoted for this compound — the 1%, the 40%, the 8% discontinuation — was measured under that ceiling. Quoting them for a schedule that exceeds it is quoting a number for an experiment nobody ran.
Sources read for this page
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology 2019 · PMID 31599840
- U.S. Food and Drug Administration. VYLEESI (bremelanotide injection), for subcutaneous use — full prescribing information. DailyMed, U.S. National Library of Medicine
- Semple EA, et al. Melanocortin 4 receptor signaling in Sim1 neurons permits sexual receptivity in female mice. Frontiers in Endocrinology 2023 · PMID 37033219
- Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, Obesity and Metabolism 2022 · PMID 35170192
- Parish SJ, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine 2021 · PMID 33814355
- Böhm M, et al. An overview of benefits and risks of chronic melanocortin-1 receptor activation. Journal of the European Academy of Dermatology and Venereology 2024 · PMID 39082868
PT-141 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are melanocortin receptor agonists and they are not selective, which is the whole safety story. MC1R gives the tanning. MC4R gives the nausea, the flushing and the erections. You do not get to choose which receptors respond.
- The mole question is the one that matters. These drive melanogenesis systemically — existing naevi commonly darken and new ones can appear. That is not itself cancer, but it makes melanoma surveillance harder precisely in people using a tanning agent.
What has actually been reported
- Nausea in the first hours after dosing is very common and usually settles with repeated exposure. Facial flushing, spontaneous erections and appetite suppression are all frequently reported.
- Case reports exist of melanoma diagnosed in Melanotan users. Causation is not established and the population self-selects for sun exposure — but 'unproven' is not 'reassuring' here.
How to reduce the risk
Same mechanism as the prediction.
- Get a full-body skin check before you start, and photograph your moles. This is the whole mitigation. The predicted problem is that melanogenesis makes surveillance harder — a dated set of baseline photographs is what makes 'has this changed?' answerable later.
- Start at a fraction of the intended dose. The nausea and flushing are MC4R effects that attenuate with exposure, so almost everyone who has a miserable first experience simply started too high.
- Dose in the evening. If the nausea lands, you sleep through the worst of it.
- Sun protection does not become optional because you tan faster. Melanin is partial protection, and the tan is not the part that matters here — the mole surveillance is.
- Any new lesion, or an existing one that changes shape, color or border, is a dermatologist appointment rather than a forum question.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks this. The monitoring here is dermatological, not hematological — get a skin check and photograph your moles before you start.
Don't run this if
- Personal or family history of melanoma, or many atypical moles.
- Any pigmented lesion you have not had looked at.
The honest unknown
- Whether driving melanogenesis for years changes melanoma risk in humans. Nobody has run that study and it is not obvious anyone will.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Food is not a factor — pick a time you will keep
Nothing you eat touches a subcutaneous injection, so there is no meal to plan around. What does matter is a fixed slot: the commonest reason an injectable protocol underperforms is missed doses, not mistimed ones.
With a short half-life, dose it near the effect you want rather than at a fixed hour.
From half-life and route, not a dosing trial.
PT-141 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What PT-141 moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Blood pressure is the thing to watch here and it is not a lab — melanocortin agonists can raise it transiently after dosing.
What to do: Take blood pressure before and an hour after a dose the first few times. That tells you more than any panel.
The mechanism-predicted concern that matters is not on a blood panel: melanocortin agonists stimulate melanocytes, so existing moles darkening or changing is the signal to take seriously, and a skin check before starting is the version of a baseline that applies here.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside PT-141
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Total Testosterone | Rule out the hormonal cause before treating the symptom |
| Free Testosterone | The fraction that actually acts |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Erectile difficulty is a vascular warning — this is the vascular check |
| HbA1c (Hemoglobin A1c) | Diabetes is a leading cause, and it's silent for years |
The ED & Low Libido panel covers these in one order — 11 markers, $202.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
PT-141 — frequently asked questions
What is PT-141 (bremelanotide)?
PT-141 is a melanocortin-receptor agonist peptide for sexual health that acts on desire in the brain. It's FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
How does PT-141 work?
It activates MC4R in the hypothalamus/limbic system — the brain circuitry of sexual desire and arousal. Unlike Viagra-type drugs, it works centrally on desire, not on blood flow, so it targets 'wanting,' not just erectile plumbing.
Does PT-141 work for men?
Its FDA approval (Vyleesi) is for premenopausal women with HSDD. Off-label, it's used by men for low libido or ED that doesn't fully respond to PDE5 inhibitors, and sometimes combined with them since the mechanisms are complementary. That use is off-label.
How is PT-141 dosed?
As Vyleesi, it's a subcutaneous auto-injector taken on demand at least 45 minutes before activity, with a defined maximum frequency (not daily). Research-market versions also come as a nasal spray. This is educational, not dosing advice.
What are the side effects of PT-141?
Most commonly nausea (especially early), flushing and headache. It can transiently raise blood pressure (cautioned in cardiovascular disease) and cause temporary skin/gum darkening with repeated use via MC1R.
Is PT-141 FDA-approved?
Yes — as Vyleesi, for HSDD in premenopausal women. Use in men is off-label, and research-market PT-141 is unapproved material.
References & further reading
- PT-141 (bremelanotide): melanocortin-based approach (Superpower)
- PT-141 (bremelanotide) clinical guide for physicians (Enavvi)
PT-141 inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What PT-141 is used for
PT-141 appears under 1 goal in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
PT-141 is the central arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.